# First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer

> **NCT03873883** · PHASE1 · COMPLETED · sponsor: **iTeos Therapeutics** · enrollment: 119 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** EOS100850
- **DRUG:** Pembrolizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03873883
- **Lead sponsor:** iTeos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-05
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03873883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03873883, "First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03873883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*